Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9

References

• Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17:43 - 52; http://dx.doi.org/10.1016/0092-8674(79)90293-9; PMID: 222475
   PubMed Web of Science ®Google Scholar
• Kress M, May E, Cassingena R, May P. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol 1979; 31:472 - 83; PMID: 225566
   PubMed Web of Science ®Google Scholar
• Melero JA, Stitt DT, Mangel WF, Carroll RB. Identification of new polypeptide species (48-55K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells. Virology 1979; 93:466 - 80; http://dx.doi.org/10.1016/0042-6822(79)90250-2; PMID: 222051
   PubMed Web of Science ®Google Scholar
• Smith AE, Smith R, Paucha E. Characterization of different tumor antigens present in cells transformed by simian virus 40. Cell 1979; 18:335 - 46; http://dx.doi.org/10.1016/0092-8674(79)90053-9; PMID: 227604
   PubMed Web of Science ®Google Scholar
• Lane DR, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells.. Nature 1979; 278:261 - 3; PMID: 218111
   PubMed Web of Science ®Google Scholar
• Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6:909 - 23; http://dx.doi.org/10.1038/nrc2012; PMID: 17128209
   PubMed Web of Science ®Google Scholar
• Crook T, Vousden KH. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J 1992; 11:3935 - 40; PMID: 1327751
   PubMed Web of Science ®Google Scholar
• Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85:200 - 6; http://dx.doi.org/10.1093/jnci/85.3.200; PMID: 8423624
   PubMed Web of Science ®Google Scholar
• Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995; 75:1327 - 38; http://dx.doi.org/10.1002/1097-0142(19950315)75:6<1327::AID-CNCR2820750615>3.0.CO;2-P; PMID: 7882283
   PubMed Web of Science ®Google Scholar
• Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011; 223:116 - 26; http://dx.doi.org/10.1002/path.2784; PMID: 21125670
   PubMed Web of Science ®Google Scholar
• IARC TP53 Mutation Database [Internet]. Available from: http://www-p53.iarc.fr/Statistics.html
   Google Scholar
• Watcharasit P, Bijur GN, Zmijewski JW, Song L, Zmijewska A, Chen X, et al. Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc Natl Acad Sci USA 2002; 99:7951 - 5; http://dx.doi.org/10.1073/pnas.122062299; PMID: 12048243
   PubMed Web of Science ®Google Scholar
• Thukral SK, Blain GC, Chang KK, Fields S. Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2. Mol Cell Biol 1994; 14:8315 - 21; PMID: 7969167
   PubMed Web of Science ®Google Scholar
• Schlamp CL, Poulsen GL, Nork TM, Nickells RW. Nuclear exclusion of wild-type p53 in immortalized human retinoblastoma cells. J Natl Cancer Inst 1997; 89:1530 - 6; http://dx.doi.org/10.1093/jnci/89.20.1530; PMID: 9337350
   PubMed Web of Science ®Google Scholar
• Bosari S, Viale G, Roncalli M, Graziani D, Borsani G, Lee AK, et al. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 1995; 147:790 - 8; PMID: 7677190
   PubMed Web of Science ®Google Scholar
• Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992; 89:7262 - 6; http://dx.doi.org/10.1073/pnas.89.15.7262; PMID: 1353891
   PubMed Web of Science ®Google Scholar
• Moll UM, LaQuaglia M, Bénard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 1995; 92:4407 - 11; http://dx.doi.org/10.1073/pnas.92.10.4407; PMID: 7753819
   PubMed Web of Science ®Google Scholar
• Stenmark-Askmalm M, Stål O, Sullivan S, Ferraud L, Sun XF, Carstensen J, et al. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer 1994; 30A:175 - 80; http://dx.doi.org/10.1016/0959-8049(94)90082-5; PMID: 7908819
   PubMedGoogle Scholar
• Sun XF, Carstensen JM, Zhang H, Stål O, Wingren S, Hatschek T, et al. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992; 340:1369 - 73; http://dx.doi.org/10.1016/0140-6736(92)92558-W; PMID: 1360088
   PubMed Web of Science ®Google Scholar
• Høgdall EVS, Christensen L, Høgdall CK, Frederiksen K, Gayther S, Blaakaer J, et al. Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas. APMIS 2008; 116:400 - 9; http://dx.doi.org/10.1111/j.1600-0463.2008.00917.x; PMID: 18452430
   PubMed Web of Science ®Google Scholar
• Ghavam-Nasiri MR, Rezaei E, Ghafarzadegan K, Seilanian-Toosi M, Malekifard H. Expression of p53 in colorectal carcinoma: correlation with clinicopathologic features. Arch Iran Med 2007; 10:38 - 42; PMID: 17198452
   PubMed Web of Science ®Google Scholar
• Guillou L, Estreicher A, Chaubert P, Hurlimann J, Kurt AM, Metthez G, et al. Germ cell tumors of the testis overexpress wild-type p53. Am J Pathol 1996; 149:1221 - 8; PMID: 8863671
   PubMed Web of Science ®Google Scholar
• Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, Criollo A, et al. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 2008; 7:3056 - 61; http://dx.doi.org/10.4161/cc.7.19.6751; PMID: 18818522
   PubMed Web of Science ®Google Scholar
• Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S, et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 2011; 7:285 - 95; http://dx.doi.org/10.1038/nchembio.546; PMID: 21445056
   PubMed Web of Science ®Google Scholar
• Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011; 20:79 - 91; http://dx.doi.org/10.1016/j.ccr.2011.06.004; PMID: 21741598
   PubMed Web of Science ®Google Scholar
• Martynova E, Pozzi S, Basile V, Dolfini D, Zambelli F, Imbriano C, et al. Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63. Oncotarget 2012; 3:132 - 43; PMID: 22361592
   PubMed Web of Science ®Google Scholar
• Frank AK, Pietsch EC, Dumont P, Tao J, Murphy ME. Wild-type and mutant p53 proteins interact with mitochondrial caspase-3. Cancer Biol Ther 2011; 11:740 - 5; http://dx.doi.org/10.4161/cbt.11.8.14906; PMID: 21307660
   PubMed Web of Science ®Google Scholar
• Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999; 68:383 - 424; http://dx.doi.org/10.1146/annurev.biochem.68.1.383; PMID: 10872455
   PubMed Web of Science ®Google Scholar
• Zhivotovsky B, Samali A, Gahm A, Orrenius S. Caspases: their intracellular localization and translocation during apoptosis. Cell Death Differ 1999; 6:644 - 51; http://dx.doi.org/10.1038/sj.cdd.4400536; PMID: 10453075
   PubMed Web of Science ®Google Scholar
• Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 1992; 66:373 - 85; http://dx.doi.org/10.1038/bjc.1992.273; PMID: 1503912
   PubMed Web of Science ®Google Scholar
• Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237 - 45; http://dx.doi.org/10.1016/0092-8674(92)90644-R; PMID: 1535557
   PubMed Web of Science ®Google Scholar
• MacLachlan TK, El-Deiry WS. Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci USA 2002; 99:9492 - 7; http://dx.doi.org/10.1073/pnas.132241599; PMID: 12089322
   PubMed Web of Science ®Google Scholar
• Wong RPC, Tsang WP, Chau PY, Co NN, Tsang TY, Kwok TT. p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol Cancer Ther 2007; 6:1054 - 61; http://dx.doi.org/10.1158/1535-7163.MCT-06-0336; PMID: 17363498
   PubMed Web of Science ®Google Scholar
• Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 2000; 14:2060 - 71; PMID: 10950869
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303:1010 - 4; http://dx.doi.org/10.1126/science.1092734; PMID: 14963330
   PubMed Web of Science ®Google Scholar
• Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001; 276:3238 - 46; http://dx.doi.org/10.1074/jbc.M003670200; PMID: 11024045
   PubMed Web of Science ®Google Scholar
• Shiozaki EN, Chai J, Rigotti DJ, Riedl SJ, Li P, Srinivasula SM, et al. Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 2003; 11:519 - 27; http://dx.doi.org/10.1016/S1097-2765(03)00054-6; PMID: 12620238
   PubMed Web of Science ®Google Scholar
• Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388:300 - 4; http://dx.doi.org/10.1038/40901; PMID: 9230442
   PubMed Web of Science ®Google Scholar
• Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001; 410:112 - 6; http://dx.doi.org/10.1038/35065125; PMID: 11242052
   PubMed Web of Science ®Google Scholar
• Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1998; 1:949 - 57; http://dx.doi.org/10.1016/S1097-2765(00)80095-7; PMID: 9651578
   PubMed Web of Science ®Google Scholar
• Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, Okazaki T, et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med 1998; 187:587 - 600; http://dx.doi.org/10.1084/jem.187.4.587; PMID: 9463409
   PubMed Web of Science ®Google Scholar
• Cowling V, Downward J. Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain. Cell Death Differ 2002; 9:1046 - 56; http://dx.doi.org/10.1038/sj.cdd.4401065; PMID: 12232792
   PubMed Web of Science ®Google Scholar
• Stennicke HR, Jürgensmeier JM, Shin H, Deveraux Q, Wolf BB, Yang X, et al. Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem 1998; 273:27084 - 90; http://dx.doi.org/10.1074/jbc.273.42.27084; PMID: 9765224
   PubMed Web of Science ®Google Scholar
• Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A, et al. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA 2008; 105:10703 - 8; http://dx.doi.org/10.1073/pnas.0712034105; PMID: 18669646
   PubMed Web of Science ®Google Scholar
• Stegh AH, DePinho RA. Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. Cell Cycle 2011; 10:33 - 8; http://dx.doi.org/10.4161/cc.10.1.14365; PMID: 21200141
   PubMed Web of Science ®Google Scholar
• Leong SM, Tan BX, Bte Ahmad B, Yan T, Chee LY, Ang ST, et al. Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition. Blood 2010; 116:3286 - 96; http://dx.doi.org/10.1182/blood-2009-12-256149; PMID: 20606168
   PubMed Web of Science ®Google Scholar
• Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000; 102:849 - 62; http://dx.doi.org/10.1016/S0092-8674(00)00073-8; PMID: 11030628
   PubMed Web of Science ®Google Scholar
• Stenger JE, Tegtmeyer P, Mayr GA, Reed M, Wang Y, Wang P, et al. p53 oligomerization and DNA looping are linked with transcriptional activation. EMBO J 1994; 13:6011 - 20; PMID: 7813439
   PubMed Web of Science ®Google Scholar
• Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299 - 303; http://dx.doi.org/10.1038/387299a0; PMID: 9153396
   PubMed Web of Science ®Google Scholar
• Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36:59 - 74; http://dx.doi.org/10.1099/0022-1317-36-1-59; PMID: 886304
   PubMed Web of Science ®Google Scholar
• König C, Roth J, Dobbelstein M. Adenovirus type 5 E4orf3 protein relieves p53 inhibition by E1B-55-kilodalton protein. J Virol 1999; 73:2253 - 62; PMID: 9971808
   PubMed Web of Science ®Google Scholar
• Blair Zajdel ME, Blair GE. The intracellular distribution of the transformation-associated protein p53 in adenovirus-transformed rodent cells. Oncogene 1988; 2:579 - 84; PMID: 3290806
   PubMed Web of Science ®Google Scholar
• Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11:577 - 90; http://dx.doi.org/10.1016/S1097-2765(03)00050-9; PMID: 12667443
   PubMed Web of Science ®Google Scholar
• Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91:479 - 89; http://dx.doi.org/10.1016/S0092-8674(00)80434-1; PMID: 9390557
   PubMed Web of Science ®Google Scholar
• Murphy RF, Komlodi-Pasztor E, Robey R, Balis FM, Farrell NP, Fojo T. Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. Cell Cycle 2012; 11:963 - 73; http://dx.doi.org/10.4161/cc.11.5.19447; PMID: 22333583
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells. Oncotarget 2012; 3:601 - 7; PMID: 22802145
   PubMed Web of Science ®Google Scholar
• Bell S, Hansen S, Buchner J. Refolding and structural characterization of the human p53 tumor suppressor protein. Biophys Chem 2002; 96:243 - 57; http://dx.doi.org/10.1016/S0301-4622(02)00011-X; PMID: 12034444
   PubMed Web of Science ®Google Scholar
• Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, et al. Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin Cancer Res 2011; 17:494 - 504; http://dx.doi.org/10.1158/1078-0432.CCR-10-1587; PMID: 21098696
   PubMed Web of Science ®Google Scholar